Porcine blood and surrogate markers do not prove benefit of aDabi-Fab

While we read with great interest the recent report concerning the reversal of dabigatran-induced coagulopathy [1], we are concerned that methodological issues limit the validity of the authors’ conclusions. Firstly, it is unclear why a porcine model was utilized. Although there is clinical relevance for testing reversal agents in a trauma model, all agents were administered ex vivo. Furthermore, the established correlation between the activated partial thromboplastin time (aPTT) and dabigatran concentrations in humans [2] is absent in the pig model. Potentially, porcine coagulation pa-